03:21 AM EDT, 08/19/2026 (MT Newswires) -- RTW Biotech Opportunities' (RTW.L) portfolio company, Alesta Therapeutics, will be acquired by US-based biotechnology company BioMarin Pharmaceutical (BM8.F) in a definitive deal worth up to $490 million, according to a Wednesday filing. BioMarin will pay $275 million cash upfront and up to an additional $215 million on the achievement of certain milestones for Alesta's lead asset ALE1, which is in development for hypophosphatasia. Before deal completion, which is expected in the third quarter of 2026, the clinical-stage biotechnology company will transfer all non-ALE1 assets to a newly-formed entity, in which RTW Bio and other existing Alesta shareholders will retain their pro rata stake. The value of RTW's holding in Alesta was $3.8 million, representing 0.4% of the London-listed life sciences-focused investor's net asset value, as of July 31.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.